Carleton Scott Ellis is a pharmacist who is specialized in Oncology in Lexington, Kentucky. Patients can reach him at 800 Rose St, Lexington or contact him on 859-323-2650. Active license number of Carleton Scott Ellis is 019946 for Oncology in Kentucky. Carleton Scott Ellis is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Carleton Scott Ellis speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Carleton Scott Ellis
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Male
Location:
800 Rose St, Lexington, Kentucky, 40536-7001
Phone:
859-323-2650
Fax:
859-323-0702
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Carleton Scott Ellis are as mentioned below.
NPI Number:
1164928420
NPI Enumeration Date:
04 Apr, 2018
NPI Last Update On:
18 Oct, 2022
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Carleton Scott Ellis are as mentioned below.
Specialization
License Number
State
Status
Oncology
019946
Kentucky
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
800 Rose St, Lexington, Kentucky
Zip:
40536-7001
Phone Number:
859-323-2650
Fax Number:
859-323-0702
Patients can reach Carleton Scott Ellis at 800 Rose St, Lexington, Kentucky or can call on phone at 859-323-2650.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.